Figure 2.
DzT overcomes TKI resistance in EGFR T790M mutant cells. Gefitinib (1 μmol/l; a) or DzT- (100 nmol/l; b) treated cells were analyzed by immunoblotting with the indicated primary antibodies listed on the left. EGF (100 ng/ml) was added to CL1-5wt 15 min before cell lysis. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors.